

ModernGraham Valuation

Company Name:

Luminex Corporation

Company Ticker LMNX

Date of Analysis

3/25/2017



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$743,603,870	Fail
2. Sufficiently Strong Financial Condition	Current Ratio > 2	4.32	Pass
3. Earnings Stability	Positive EPS for 10 years prior		Pass
4. Dividend Record	Dividend Payments for 10 years prior		Fail
	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	107.94%	Pass
5. Earnings Growth	PEmg < 20	41.65	Fail
6. Moderate PEmg Ratio	PB Ratio < 2.5 OR PB*PEmg < 50	1.93	Pass
7. Moderate Price to Assets			

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	4.32	Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	0.00	Pass
3. Earnings Stability	Positive EPS for 5 years prior		Pass
4. Dividend Record	Currently Pays Dividend		Fail
5. Earnings Growth	EPSmg greater than 5 years ago		Pass
	Score		

Suitability

Defensive	No
Enterprising	Yes

Stage 2: Determination of Intrinsic Value

EPSmg	\$0.44
MG Growth Estimate	11.23%
MG Value	\$13.50
MG Value based on 3% Growth	\$6.32
MG Value based on 0% Growth	\$3.71
Market Implied Growth Rate	16.58%

MG Opinion

Current Price	\$18.16
% of Intrinsic Value	134.53%
Opinion	Overvalued
MG Grade	C-

Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	\$2.95
Graham Number	\$5.21
PEmg	41.65
Current Ratio	4.32
PB Ratio	1.93
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links:

ModernGraham tagged articles	Morningstar
Google Finance	MSN Money
Yahoo Finance	Seeking Alpha
GuruFocus	SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate		Next Fiscal Year Estimate	
	\$0.13		\$0.44
Dec2016	\$0.32	Dec2016	\$0.56
Dec2015	\$0.86	Dec2015	\$0.63
Dec2014	\$0.93	Dec2014	\$0.47
Dec2013	\$0.17	Dec2013	\$0.25
Dec2012	\$0.30	Dec2012	\$0.28
Dec2011	\$0.34	Dec2011	\$0.24
Dec2010	\$0.12	Dec2010	\$0.16
Dec2009	\$0.43	Dec2009	\$0.15
Dec2008	\$0.08	Dec2008	\$0.00
Dec2007	-\$0.08	Dec2007	-\$0.06
Dec2006	\$0.05	Dec2006	-\$0.11
Dec2005	-\$0.09	Dec2005	-\$0.24
Dec2004	-\$0.12	Dec2004	-\$0.36
Dec2003	-\$0.14	Dec2003	-\$0.52
Dec2002	-\$0.85	Dec2002	-\$0.69
Dec2001	-\$0.55	Dec2001	-\$0.57
Dec2000	-\$0.52	Balance Sheet Information 12/1/2016	
Dec1999	-\$0.96	Total Current Assets	\$173,737,000
Dec1998	-\$0.43	Total Current Liabilities	\$40,200,000
Dec1997	\$0.00	Long-Term Debt	\$0
		Total Assets	\$450,716,000
		Intangible Assets	\$173,889,000
		Total Liabilities	\$47,037,000
		Shares Outstanding (Diluted Average)	43,013,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other
ModernGraham
posts about the
company

#N/A

Other
ModernGraham
posts about related
companies

[LHC Group Inc Valuation – Initial Coverage \\$LHCG](#)
[Dentsply Sirona Inc Valuation – March 2017 \\$XRAY](#)
[Landauer Inc Valuation – Initial Coverage \\$LDR](#)
[IDEXX Laboratories Inc Valuation – Initial Coverage \\$IDXX](#)
[Hologic Inc Valuation – Initial Coverage \\$HOLX](#)
[Mettler-Toledo International Inc Valuation – Initial Coverage \\$MTD](#)
[Envision Healthcare Corp Valuation – Initial Coverage \\$EVHC](#)
[UnitedHealth Group Inc Valuation – February 2017 \\$UNH](#)
[Davita Inc Valuation – February 2017 \\$DVA](#)
[Steris PLC Valuation – Initial Coverage \\$STE](#)